WHO Pharmaceuticals Newsletter 2004, No. 01
(2004; 17 pages) Voir le document au format PDF
Table des matières
Ouvrir ce répertoire et afficher son contenuREGULATORY MATTERS
Fermer ce répertoireSAFETY OF MEDICINES
Afficher le documentANTIEPILEPTICS - ADR update from Australia
Afficher le documentBOTULINUM TOXIN TYPE A - Place in therapy not clearly defined
Afficher le documentCELECOXIB/ROFECOXIB - Acute temporary visual impairment
Afficher le documentDACLIZUMAB - Increased mortality in cardiac transplant patients
Afficher le documentFLUTICASONE - Update on adrenal insufficiency reports
Afficher le documentINTERFERON BETA - Safety information about risk of liver injury
Afficher le documentMETHADONE - Risk of QT prolongation
Afficher le documentMETHOTREXATE - Update on pulmonary effects
Afficher le documentMIRTAZAPINE - ADR update from Australia
Afficher le documentMORPHINE - Accidental overdose of concentrated oral solutions
Afficher le documentNONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDs) - Postpartum administration may cause hypertension
Afficher le documentPERGOLIDE - Danger of falling asleep during daily activities
Afficher le documentPYRAZINAMIDE & RIFAMPICIN - Serious liver injury with combined use in latent tuberculosis
Afficher le documentSIBUTRAMINE - ADR update
Afficher le documentTOPIRAMATE - Warning about metabolic acidosis
Afficher le documentWARFARIN - Interaction with cranberry juice
Ouvrir ce répertoire et afficher son contenuDRUGS OF CURRENT INTEREST
Ouvrir ce répertoire et afficher son contenuFEATURE
 

MORPHINE - Accidental overdose of concentrated oral solutions

USA. Accidental overdose of concentrated oral morphine solutions has resulted in serious adverse events and deaths, according to a ‘Dear Healthcare Professional’ letter issued by Elan Pharmaceuticals in the United States. In most cases, oral morphine solutions that were ordered in mg were mistakenly interchanged for mL, resulting in a 20-fold overdose. Elan distributes three concentrated oral solutions containing morphine 20 mg/mL (Roxanol, Roxanol-T and Roxanol 100). In order to prevent medication errors, the company has requested that prescribers write prescriptions for oral morphine solutions clearly stating the required concentration of oral solution, the intended morphine dose in mg and the corresponding volume in mL.

Reference:
‘Dear Healthcare Professional’ letter from Elan Pharmaceuticals, October 2003. Available from URL: http://www.fda.gov

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013